tiprankstipranks
Trending News
More News >
Carl Zeiss Meditec (DE:AFX)
XETRA:AFX

Carl Zeiss Meditec (AFX) AI Stock Analysis

Compare
86 Followers

Top Page

DE

Carl Zeiss Meditec

(XETRA:AFX)

Rating:64Neutral
Price Target:
€63.00
▲(3.36%Upside)
Carl Zeiss Meditec's overall stock score is driven by strong financial performance and a stable balance sheet, though moderated by high valuation and bearish technical indicators. The lack of earnings call and corporate events data places more emphasis on these factors.
Positive Factors
Chinese Market Growth
Management mentions a clear upturn in refractive consumables in China, indicating a positive Chinese growth contribution.
Earnings Performance
Carl Zeiss Meditec released preliminary figures that were a substantial beat on topline and EBITA.
New Product Launches
MCS was positively driven by the ongoing Kinevo 900S launch, reflecting stronger performance relative to consensus.
Negative Factors
Macro Environment Challenges
The China Refractive business, which historically had been an important driver of earnings growth and a key element of the equity thesis, slowed as a result of a soft macro environment and downtrading.
Profitability Concerns
There may be questions over DORC's profitability as operating expenses are mounting.
Tariff Impact
Tariffs notably affect manufacturing in Germany and Singapore, which could impact guidance adjustments.

Carl Zeiss Meditec (AFX) vs. iShares MSCI Germany ETF (EWG)

Carl Zeiss Meditec Business Overview & Revenue Model

Company DescriptionCarl Zeiss Meditec (AFX) is a prominent player in the medical technology sector, specializing in the development and distribution of cutting-edge solutions for ophthalmology and microsurgery. As a subsidiary of the global optics and optoelectronics company Carl Zeiss AG, the company provides innovative products such as diagnostic and surgical systems for eye care professionals and surgeons worldwide.
How the Company Makes MoneyCarl Zeiss Meditec generates revenue through the sale of its advanced medical devices and systems that cater to the needs of ophthalmologists and surgeons. The company's revenue streams predominantly include direct sales of equipment like optical coherence tomography systems, surgical microscopes, and intraocular lenses. Additionally, the company benefits from service contracts, maintenance agreements, and the sale of consumables related to its products. Strategic partnerships and collaborations with healthcare institutions and research organizations further bolster its market presence and drive sales. These diverse revenue streams enable Carl Zeiss Meditec to maintain a robust financial performance in the competitive medical technology industry.

Carl Zeiss Meditec Financial Statement Overview

Summary
Carl Zeiss Meditec exhibits strong profitability and effective equity utilization, with good operational efficiency. The company maintains a low debt profile, enhancing its financial stability. However, growth rates have moderated, and there is potential risk from liabilities that could impact future financial flexibility. Management should focus on reinvigorating growth and maintaining a healthy balance between liabilities and equity.
Income Statement
78
Positive
Carl Zeiss Meditec shows a strong Gross Profit Margin and consistent Net Income growth, indicating solid profitability and operational efficiency. The Revenue Growth Rate is positive but has slowed down in recent years, suggesting a potential plateau in growth. Both EBIT and EBITDA margins are healthy, indicating good control over costs.
Balance Sheet
72
Positive
The company's Debt-to-Equity Ratio is low, showing strong solvency and low reliance on debt financing. ROE is robust, emphasizing effective use of equity to generate profits. However, the Equity Ratio is relatively low due to substantial liabilities, which could pose a risk if not managed carefully.
Cash Flow
65
Positive
The company has a stable Free Cash Flow, although growth has been modest. Operating Cash Flow to Net Income Ratio is strong, reflecting efficient cash generation from operations. However, Free Cash Flow to Net Income has fluctuated, indicating variability in cash availability for reinvestment and financing.
Breakdown
TTMSep 2024Sep 2023Sep 2022Sep 2021Sep 2020
Income StatementTotal Revenue
2.56B2.07B2.09B1.90B1.65B1.34B
Gross Profit
1.56B1.09B1.21B1.13B967.21M745.52M
EBIT
315.24M176.35M327.14M413.08M348.42M206.60M
EBITDA
251.80M406.08M502.77M482.36M409.21M266.41M
Net Income Common Stockholders
157.03M178.73M290.40M293.91M236.28M122.39M
Balance SheetCash, Cash Equivalents and Short-Term Investments
33.75M20.29M10.60M7.73M7.44M5.20M
Total Assets
2.92B3.39B3.03B2.82B2.40B2.01B
Total Debt
142.01M151.35M155.70M127.90M121.27M68.61M
Net Debt
126.67M131.06M145.09M120.17M113.83M63.40M
Total Liabilities
812.91M1.34B860.02M792.73M718.59M562.73M
Stockholders Equity
2.09B2.04B2.16B2.02B1.66B1.43B
Cash FlowFree Cash Flow
-12.34M95.11M137.00M106.23M296.56M133.54M
Operating Cash Flow
220.02M247.32M250.86M188.20M362.66M178.53M
Investing Cash Flow
-429.50M-412.31M-110.98M-148.89M-75.20M-71.95M
Financing Cash Flow
223.65M176.25M-135.09M-38.24M-285.89M-122.96M

Carl Zeiss Meditec Technical Analysis

Technical Analysis Sentiment
Positive
Last Price60.95
Price Trends
50DMA
58.46
Positive
100DMA
58.12
Positive
200DMA
57.66
Positive
Market Momentum
MACD
-0.22
Negative
RSI
55.76
Neutral
STOCH
90.44
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:AFX, the sentiment is Positive. The current price of 60.95 is above the 20-day moving average (MA) of 59.48, above the 50-day MA of 58.46, and above the 200-day MA of 57.66, indicating a bullish trend. The MACD of -0.22 indicates Negative momentum. The RSI at 55.76 is Neutral, neither overbought nor oversold. The STOCH value of 90.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:AFX.

Carl Zeiss Meditec Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
DEEUZ
78
Outperform
€1.35B39.3317.48%0.08%15.89%14.62%
77
Outperform
€1.19B10.798.06%2.84%0.51%
DEFME
68
Neutral
€14.76B23.884.37%2.86%0.10%27.83%
DEBIO
68
Neutral
€1.40B64.15-4.72%0.09%-18.82%-113.85%
DEAFX
64
Neutral
€5.38B33.947.48%1.01%5.21%-39.36%
DESRT
63
Neutral
€12.87B120.733.55%0.44%3.99%-36.36%
54
Neutral
$5.31B3.28-45.10%2.80%16.76%0.02%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:AFX
Carl Zeiss Meditec
60.10
-25.06
-29.43%
DE:FME
Fresenius Medical Care AG & Co. KGaA
50.10
11.83
30.91%
DE:SRT
Sartorius
166.40
-32.56
-16.36%
DE:BIO
Biotest
42.20
1.20
2.93%
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
66.75
24.21
56.89%
DE:DRW3
Draegerwerk AG & Co. KGaA
72.00
23.25
47.70%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.